Inovalon Unveils New Capabilities Across the Healthcare Continuum to Drive Smarter, More Connected Care and Operations
Leading Data and Solutions Company Broadens Platform and Feature Sets Across Providers, Payers, Pharmacies, and more...
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the more...
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 17
IRVINE, Calif.--(BUSINESS WIRE)--#Healthcare--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a more...
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Lung06 phase more...
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery more...
Aptar Reports Third Quarter 2025 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product more...
Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today more...
Community Health Systems Announces Definitive Agreement to Sell Ownership Interests in Clarksville, Tennessee, Hospital to Vanderbilt University Medical Center
FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company more...
Vizient Applauds FDA’s Recent Actions to Accelerate Biosimilar Development and Lower Costs
IRVING, Texas--(BUSINESS WIRE)--Vizient® commends the U.S. Food and Drug Administration (FDA) for announcing actions to more...
Grove to Report Third Quarter 2025 Financial Results on November 13, 2025
SAN FRANCISCO--(BUSINESS WIRE)--$GROV--Grove Collaborative Holdings, Inc. (NYSE: GROV) (“Grove” or “the Company”), the world’s first more...